regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
As of 2014, it has 450 employees working at 3 locations, including distribution centers in North Las Vegas, NV; Shiremanstown, PA; and Bedfordshire, U.K. The corporate headquarters is also located in Boise, along with the company's customer service call center. In 2013, the company donated the equipment for Boise's first outdoor gym, located in Ann Morrison Park. In September 2015, Ryan Deluca suddenly announced he would be stepping down from his position as CEO. In November, Liberty Interactive spun off Bodybuilding.com and its stake in Expedia into a new company, Liberty Expedia Holdings. After Bodybuilding.com laid off 90 people in December 2016, it reorganized to form 4 different companies/brands. In February 2019, hackers accessed some part of Bodybuilding.com's corporate IT systems, and may have retrieved personal data of the site's users. Sometime in the next few months, the company discovered this, but did not publicize it right away, instead hiring a security company to assess what their vulnerability had been. It was found that at least one of Bodybuilding.com's 450 employees had been susceptible to a phishing email sent in July 2018. It was not determined if the hackers accessed user data. In April 2019, Bodybuilding.com publicized the breach, saying its consequences were unknown, and reset all the passwords of the site's users.
As a result of tight advertising and marketing prohibitions, tobacco companies view packaging as a vital factor in displaying brand imagery and creating in-store presence at the point of purchase. Market testing shows the influence of this dimension in shifting the consumer's choice when the same product is displayed in alternative packaging. Companies have manipulated a variety of elements on packaging designs to communicate the impression of lower tar content or milder cigarettes, although the actual contents were the same. Some countries require cigarette packs to display warnings about the health impact of smoking. The United States was the first, later followed by other countries including Canada, most of Europe, the United Kingdom, Australia, Pakistan, India and Hong Kong. In 1985, Iceland became the first country to enforce graphic warnings on cigarette packaging. At the end of December 2010, new regulations in Canada increased the size of tobacco warnings to cover three-quarters of cigarette packaging. As of November 2010, 39 countries have adopted similar legislation. In February 2011, the Canadian government passed regulations requiring cigarette packaging to contain 12 new images to cover three quarters of the outside panel and eight new health messages on the inside panel with full color. As of April 2011, Australian regulations require all packaging to use a bland olive green that researchers determined to be the least attractive color, with 75% coverage on the front of the pack and all of the back consisting of graphic health warnings.
==== Liver and gastrointestinal ==== Hepatobiliary MRI is used to detect and characterize lesions of the liver, pancreas, and bile ducts. Focal or diffuse disorders of the liver may be evaluated using diffusion-weighted, opposed-phase imaging and dynamic contrast enhancement sequences. Extracellular contrast agents are used widely in liver MRI, and newer hepatobiliary contrast agents also provide the opportunity to perform functional biliary imaging. Anatomical imaging of the bile ducts is achieved by using a heavily T2-weighted sequence in magnetic resonance cholangiopancreatography (MRCP). Functional imaging of the pancreas is performed following administration of secretin. MR enterography provides non-invasive assessment of inflammatory bowel disease and small bowel tumors. MR-colonography may play a role in the detection of large polyps in patients at increased risk of colorectal cancer.
=== Towards type II === Viorel Badescu and Richard Cathcart have studied the possibility that a Type II civilization could use a 450 million kilometer device to direct solar radiation and thus be able to impart a kinetic motion to its star that deviates it from its usual trajectory by about 35 to 40 parsecs, allowing it, among other things, to capture its energy and navigate the galaxy. For Claude Semay, "a Type II civilization could be detected at great distances (by what is called "astro-technical leakage"), provided that it is not located in a region of the galaxy that is too distant from us, or that it does not occupy a location that is obscured from us by clouds of gas or dust".
Sources: en.wikipedia.org
The glycemic (glycaemic) index (GI; ) is a number from 0 to 100 assigned to a food, with pure glucose arbitrarily given the value of 100, which represents the relative rise in the blood glucose level two hours after consuming that food. The GI of a specific food depends primarily on the type of carbohydrate it contains, but is also affected by the amount of entrapment of the carbohydrate molecules within the food, the fat, protein content of the food, the moisture and fiber content, the amount of organic acids (or their salts) (e.g., citric or acetic acid), and the method of cooking. GI tables, which list many types of foods and their GIs, are available. A food is considered to have a low GI if it is 55 or less; high GI if 70 or more; and mid-range GI if 56 to 69. The term was introduced in 1981 by David J. Jenkins and co-workers and was created to compare the relative effects of different foods on postprandial glucose levels. It is useful for quantifying the relative rapidity with which the body breaks down carbohydrates. It takes into account only the available carbohydrate (total carbohydrate minus fiber) in a food. Glycemic index does not predict an individual's glycemic response to a food, but can be used as a tool to assess the insulin response burden of a food, averaged across a studied population. Individual responses vary greatly. The glycemic index is usually applied in the context of the quantity of the food and the amount of carbohydrate in the food that is actually consumed.
A political battle erupted over the People's Budget, which was rejected by the House of Lords and for which the government obtained an electoral mandate at the January 1910 election. The election resulted in a hung parliament, with the government left dependent on the Irish Nationalists. Although the Lords now passed the budget, the government wished to curtail their power to block legislation. Asquith was required by King George V to fight a second general election in December 1910 (whose result was little changed from that in January) before he agreed, if necessary, to create hundreds of Liberals peers. Faced with that threat, the Lords voted to give up their veto power and allowed the passage of the Parliament Act 1911. As the price of Irish support, Asquith was now forced to introduce a third Home Rule bill in 1912. Since the House of Lords no longer had the power to block the bill, but only to delay it for two years, it was due to become law in 1914. The Unionist Ulster Volunteers, led by Sir Edward Carson, launched a campaign of opposition that included the threat of a provisional government and armed resistance in Ulster. The Ulster Protestants had the full support of the Conservatives, whose leader, Bonar Law, was of Ulster-Scots descent. Government plans to deploy troops into Ulster had to be cancelled after the threat of mass resignation of their commissions by army officers in March 1914 (see Curragh Incident). Ireland seemed to be on the brink of civil war when the First World War broke out in August 1914.
On 3 December 2004, the twentieth anniversary of the disaster, a man falsely claiming to be a Dow representative named Jude Finisterra was interviewed on BBC World News. He claimed that the company had agreed to clean up the site and compensate those harmed in the accident, by liquidating Union Carbide for US$12 billion. Dow quickly issued a statement saying that they had no employee by that name—that he was an impostor, not affiliated with Dow, and that his claims were a hoax. The BBC later broadcast a correction and an apology. Jude Finisterra was actually Andy Bichlbaum, a member of the activist prankster group The Yes Men. In 2002, The Yes Men issued a fake press release explaining why Dow refused to take responsibility for the disaster and started up a website, at "DowEthics.com", designed to look like the real Dow website, but containing false information.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.